FindTrial
Sign In

A preliminary study comparing daily use of home-based hand-held Narrow Band UVB comb device versus biweekly hospital-based excimer light therapy in treatment of localized vitiligo

An open label non-randomized preliminary study comparing two targeted phototherapy devices i.e. daily use of home-based hand-held Narrow Band UVB comb device versus biweekly hospital-based excimer light therapy in treatment of localized vitiligo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/037885
Enrollment
40
Registered
2021-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: hand held NBUVB: hand-held NB-UVB comb device)-dosage of 500mJ/cm2 once daily will be administered to all vitiligo patches. Control Intervention1: Excimer lamp: dosage will be based on

Sponsors

AIIMS New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Consecutive patients of localized vitiligo i.e. 2. Patients >=18 years of age. 3. Patients who have not taken any topical therapy in last 2 weeks or systemic therapy in last 4 weeks 4. Patients giving consent for using hand held NB-UVB/excimer light

Exclusion criteria

Exclusion criteria: 1. Patients with rapidly spreading vitiligo i.e.development of >= 5 new lesions in the past 1 month or >= 15 lesions in the past 3 months. 2. Patients with recalcitrant forms of vitiligo i.e., lip-tip vitiligo, segmental vitiligo, genital vitiligo and with predominant leukotrichia on patches. 3. Patients with concomitant photo-aggravated dermatoses. 4. Patients who are unable to adhere to instructions on use of the hand-held NB-UVB comb device or maintain it or patients unable to visit the hospital for excimer light therapy

Design outcomes

Primary

MeasureTime frame
Comparison of percentage re-pigmentation of the representative vitiligo patchTimepoint: 4 months—

Secondary

MeasureTime frame
Assessment of re-pigmentation using photographic assessment (investigator global assessment)- assessment done by two independent dermatologists who are not part of the studyTimepoint: 4 months;Change in dermatology life quality index, using Tjioe M et al questionnaireTimepoint: 4 months;Comparison of degree of re-pigmentation at the end of four months in acral versus non acral sitesTimepoint: 4 months;Comparison of patientsâ?? perspective of re-pigmentation in vitiligo by Patient global assessment (PGA) score using visual analogue scale (VAS) from 0-10Timepoint: 4 months;Comparison of percentage re-pigmentation in vitiligo between the two groups based on global assessment using Lund & Browder (L & B) scoreTimepoint: 4 months;Comparison of Quality of life (QOL) score between the 2 groups using VIS-22(a vitiligo-specific QoL instrument)Timepoint: 4 months—

Countries

India

Contacts

Public ContactDr Sujay Khandpur

AIIMS New Delhi

sujay_khandpur@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026